ORIC-101   Click here for help

GtoPdb Ligand ID: 13167

Synonyms: compound 28 [PMID: 30091920] | ORIC101
Compound class: Synthetic organic
Comment: ORIC-101 is a glucocorticoid receptor (GR) antagonist [2] that is proposed to combat compensatory resistance-inducing GR signalling in advanced prostate cancer [1]
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 40.54
Molecular weight 501.74
XLogP 6.98
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)N(C)C1=CC=C(C=C1)[C@H]2C[C@@]3(C)[C@@H](CC[C@]3(C#CC(C)(C)C)O)[C@@H]4CCC5=CC(=O)CC[C@@H]5[C@H]42
Isomeric SMILES CC(C)N(C)C1=CC=C(C=C1)[C@H]2C[C@]3([C@@H](CC[C@]3(C#CC(C)(C)C)O)[C@H]4[C@H]2[C@H]5CCC(=O)C=C5CC4)C
InChI InChI=1S/C34H47NO2/c1-22(2)35(7)25-11-8-23(9-12-25)29-21-33(6)30(16-17-34(33,37)19-18-32(3,4)5)28-14-10-24-20-26(36)13-15-27(24)31(28)29/h8-9,11-12,20,22,27-31,37H,10,13-17,21H2,1-7H3/t27-,28-,29+,30-,31+,33-,34+/m0/s1
InChI Key VNLTWJIWEYPBIF-KMSLUKAPSA-N
No information available.
Summary of Clinical Use Click here for help
Clinical trials were terminated when the Investigational New Drug (IND) application for ORIC-101 was withdrawn by its developer.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03928314 Study of ORIC-101 in Combination With Anticancer Therapy Phase 1 Interventional ORIC Pharmaceuticals
NCT04033328 Study of ORIC-101 in Combination With Enzalutamide Phase 1 Interventional ORIC Pharmaceuticals In this study in patients with mCRPC progressing on enzalutamide no meaningful antitumour effect of ORIC-101 was observed. 1